Member Info for shareguard

Stumbled on this researching one of my other holdings just sharing.
https://newsmantraa.us/cancer-vaccines-market-is-anticipated-to-record-a-valuation-of-us-15845-59-million-by-2027-a-recent-study-by-the-insight-partners/

Off topic just sharingToday 00:23
Sorry for off topic interesting post if true copied off the cpx board.
Posts: 18

Price: 5.45

No Opinion

Indication of what we are up against!Mon 18:08
Copied from another site (Tremor)
RE: Shorting questionSat 11:48
Do some people here remember this post from Phoebuss….Posted in: ARB Posts: RE: Blood red ....13 Jul 2021 17:23? To all genuine investors, I lost my job today in a pay dispute, so this is my payback for how I've been treated by my employer. I work(ed) for a hedge fund in the City. There's a team of 4 of us who sit across one desk in a serviced office. Our job is to hit this board daily with FUD posts to mislead investors and influence them to sell their shares. Depending on experience we get a base salary plus bonus for every % milestone that comes off the share price We have multiple accounts/identities split into 4 categories of characters we've created:1. The blatant negative shorter who's aim is to create negative subject headings and get them pushed to the top of the chat. 2 & 3. The wingmen who back up no.1 by being negative on the stock but with more substance around why. Phoebuss 4. The concerned holder who sways from being positive about the share to win trust before then losing faith and encouraging others to do the same. Some of our aliases include:1. Mister beck, Dr Long2. 3. Phoebus (myself), jaffas, pearls, 4. Gatti, Muscles12, saby16, atrades, fudegrella30, fireant We did laugh when genuine holders agreed with some of our posts and got bonused on confirmed sell ups such as Xenor and Matt007. I'm not proud of what I've done but willing to blow the whistle to not harm any more people financially. I would encourage all of you to screenshot this post in case they report it and get it taken down but I will try on multiple threads so that it stays here longer. I am sorry.

Sorry for off topic interesting post if true copied off the cpx board.
Posts: 18

Price: 5.45

No Opinion

Indication of what we are up against!Mon 18:08
Copied from another site (Tremor)
RE: Shorting questionSat 11:48
Do some people here remember this post from Phoebuss….Posted in: ARB Posts: RE: Blood red ....13 Jul 2021 17:23? To all genuine investors, I lost my job today in a pay dispute, so this is my payback for how I've been treated by my employer. I work(ed) for a hedge fund in the City. There's a team of 4 of us who sit across one desk in a serviced office. Our job is to hit this board daily with FUD posts to mislead investors and influence them to sell their shares. Depending on experience we get a base salary plus bonus for every % milestone that comes off the share price We have multiple accounts/identities split into 4 categories of characters we've created:1. The blatant negative shorter who's aim is to create negative subject headings and get them pushed to the top of the chat. 2 & 3. The wingmen who back up no.1 by being negative on the stock but with more substance around why. Phoebuss 4. The concerned holder who sways from being positive about the share to win trust before then losing faith and encouraging others to do the same. Some of our aliases include:1. Mister beck, Dr Long2. 3. Phoebus (myself), jaffas, pearls, 4. Gatti, Muscles12, saby16, atrades, fudegrella30, fireant We did laugh when genuine holders agreed with some of our posts and got bonused on confirmed sell ups such as Xenor and Matt007. I'm not proud of what I've done but willing to blow the whistle to not harm any more people financially. I would encourage all of you to screenshot this post in case they report it and get it taken down but I will try on multiple threads so that it stays here longer. I am sorry.

ReplyRecommend (5)Report Post

https://www.safestocks.co.uk/2021/08/09/is-seeing-machines-set-to-be-taken-over-within-6-months/

Just a reminder who is the daddy

Well they dont own the shares until the 30/11/21 bigger companies may want to participate in this offer instead of them just saying.

But this could also set off on some hostile bids hope not too cheap yet.

CFP remember this great advice of yours you need to read it more often and dare i say follow it.
All his words below you dont have to go too far back to check it out Lol.

ColdFishPie

Posted in: AFC

Posts: 1,052

Price: 64.00

No Opinion

RE: Another barren week11 Nov 2021 08:07
Yes aim.....i think its best that you leave the bb.

Every post you make is just moaning about other posters and im concerned that you are creating division and negative sentiment on the bb and this might effect my investment.

For the companies sake and maybe your own...best that you stop posting and just observe from the sidelines if you feel you need to.

Just because you own afc shares does not mean that you have to post on the bb.

Let it go and you will feel better!

Hi Ratty just a reminder shortly after these two jewels were published in peer reviewed journals (one of them American) Redmile become share holders they see the potential.

https://www.lse.co.uk/rns/SCLP/publication-highlights-potential-of-avidimab-hl98138qyipcdc0.html
https://www.lse.co.uk/rns/SCLP/new-publication-highlights-potential-of-modi-1-yqnjj8pqsx583hf.html

Peer reviewed publication highlights potential of AvidiMab™ to enhance the potency of any therapeutic antibody





Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to note the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR), entitled: "Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement".1



The paper describes how Scancell's AvidiMab™ modifications to the constant region (Fc) of any antibody can improve avidity, or strength of interaction, between the antibody and its target antigen, thereby improving the antibody's potential therapeutic properties. This same modification also has demonstrated that Scancell's own tumour-associated glycan (TaG) antibodies can directly kill tumour cells.



In recent years, antibodies have become the best-selling drugs in the pharmaceutical market and have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. The global therapeutic monoclonal antibody market is estimated to be US$150 billion in 2019 and predicted to grow to US$300 billion by 2025.2



The ability to increase the potential therapeutic properties of any antibody would therefore be seen as highly advantageous. Scancell has used its AvidiMab™ technology to increase the avidity of its TaG antibodies, and these are currently being evaluated for the treatment of cancer. They are also being developed as antibody-drug conjugates (ADC).3



Professor Lindy Durrant, Chief Scientific Officer of Scancell and Corresponding Author, commented:



"We are pleased to have our work published in the prestigious, peer reviewed journal, Cancer Research. Our AvidiMab™ technology increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification also causes direct killing of cancer cells by our glycan targeting antibodies, and therefore we believe this technology has the ability to create superior candidates for cancer immunotherapy."

$300 billion market by 2025 nice timing Redmile bring it on.

How about the results being put back due to covid Australia have been pretty keen with lockdowns here is a statement from another Australian company i am in Cap-xx.
This is from an rns from this week 26th of October a 4 month lockdown

CAP-XX's Chairman, Pat Elliott, also made the following statement in relation to the Company's activities:

"After being in a four-month lockdown since the 26th of June, I am pleased to report that Sydney, and our new factory in Seven Hills, came out of lockdown on the 18th of October. Despite the impact on manning and production our Q1 sales have again been strong, up 25% on the same period last year.

Now you can zoom all you want but getting all the the right info out for result day nothing like face to face so my bet is is purely down to lock downs nothing else.
Oh you may want to take an interest in Cap-xx ticks all the boxes.
Best regards

Although 3rd one as terminated at the side:(

Not just covidity Berm two more listed ...
A Phase 2, Multicenter, Open-Label Study of SCIB1 in Patients With Advanced Unresectable Melanoma Receiving Pembrolizumab
Study of a DNA Immunotherapy to Treat Melanoma
Previous Study | Return to List | Next Study
click on one of above when accessing berms link

Scancell’s unique DNA vaccine approach is to target dendritic cells. The resultant T cell specific responses are both high frequency and high avidity. As COVID-19 research data emerges, it is becoming increasingly clear that the induction of potent and activated T cells may play a critical role in the development of long-term immunity and clearance of virus-infected cells. Scancell therefore plans to use its proven cancer vaccine concept to design a vaccine against SARS-CoV-2, the virus that causes COVID-19.
Taken from scancell website hey are starting trials soon but have chosen pharmajet needle free system for the trial. Though this doesnt mean they cant be working with n4p because John Chiplin chairman of both bit of a coincidence for me.

Looking through the science group statement not sure the board are interested in talking to anybody, given our boards running of the company dont think they have our best interest at heart will hold for now.

Rns out
https://www.lse.co.uk/rns/TPG/statement-regarding-tp-group-plc-j4ax7rkuhqukifx.html

S2020 dont be hard on your self you can only follow guidance this was PM statement in 2020 half year 30th Jan 2020.

The compelling demand for camera-based Driver Monitoring System (DMS) technology across the Automotive industry continues to be reinforced and Seeing Machines is well placed to leverage these market dynamics. The Company now counts nine ongoing program engagements with six Automotive OEMs, expected to generate a minimum of A$200m in revenue, with the bulk to be recognised between 2021 and 2024.

He too can be called deramper or perhaps Chief deramper sleep easy 2020 unless the world collapses around our feet dont think well will be in single digit pence for much longer.
Thanks to all the researchers on this board much appreciated
Best regards all

Well i have had a good day hope you have too.

So if the world is around 40000 km that makes it 181.5 times around the world a lot of data to read.....

Berm/all i for one am getting a little nervous about tomorrow i dont like 5pm rns i dont like the uncertain outcome from what a 7am RNS brings. I chucked the Zakari issue into the mix because this would be the one to ignite the share price.
The appointment of Lindy as CEO long term not good for reasons Ivy as stated so this 5pm RNS either Cliff going back to Aussie (discounting Zakari theory)or there as been significant upheaval in the boardroom. One last thought Americans do like after hours news so could well be they have instigated this and maybe release a blockbuster RNS tomorrow.

Yes but look under occupation ceo

Still active here lets see what happens tomorrow.
https://find-and-update.company-information.service.gov.uk/company/13408042/officers